{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:03:29Z","timestamp":1793678609960,"version":"4.5.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T00:00:00Z","timestamp":1659139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T00:00:00Z","timestamp":1659139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s10157-022-02253-6","type":"journal-article","created":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T17:02:37Z","timestamp":1659200557000},"page":"1092-1099","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The efficacy and safety of mizoribine for maintenance therapy in patients with myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis: the usefulness of serum mizoribine monitoring"],"prefix":"10.1007","volume":"26","author":[{"given":"Kaori","family":"Mase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joichi","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Arimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosaku","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Muso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhito","family":"Hirawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wako","family":"Yumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouichi","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Yuzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichi","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7407-0410","authenticated-orcid":false,"given":"Kunihiro","family":"Yamagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,30]]},"reference":[{"key":"2253_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65:1\u201311.","journal-title":"Arthritis Rheum"},{"key":"2253_CR2","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/art.41773","volume":"73","author":"SA Chung","year":"2021","unstructured":"Chung SA, Langford CA, Maz M, et al. 2021 American college of rheumatology\/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2021;73:1366\u201383.","journal-title":"Arthritis Rheum"},{"key":"2253_CR3","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","volume":"75","author":"M Yates","year":"2016","unstructured":"Yates M, Watts RA, Bajeme IM, et al. EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75:1583\u201394.","journal-title":"Ann Rheum Dis"},{"key":"2253_CR4","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s10157-009-0201-7","volume":"13","author":"A Koyama","year":"2009","unstructured":"Koyama A, Yamagata K, Makino H, et al. Japan RPGN registry group. A nationwide survey of rapidly progressive glomerulonephritis in Japan: etiology, prognosis and treatment diversity. Clin Exp Nephrol. 2009;13:633\u201350.","journal-title":"Clin Exp Nephrol"},{"key":"2253_CR5","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s10157-012-0598-2","volume":"16","author":"K Yamagata","year":"2012","unstructured":"Yamagata K, Usui J, Saito C, et al. ANCA-associated systemic vasculitis in Japan: clinical features and prognostic changes. Clin Exp Nephrol. 2012;16:580\u20138.","journal-title":"Clin Exp Nephrol"},{"key":"2253_CR6","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s10157-018-1663-2","volume":"23","author":"K Yamagata","year":"2019","unstructured":"Yamagata K, Usui J, Sugiyama H, Maruyama S, Narita I. Temporal change in life and renal progressive glomerulonephritis in Japan via nationwide questionnaire survey. Clin Exp Nephrol. 2019;23:573\u20135.","journal-title":"Clin Exp Nephrol"},{"key":"2253_CR7","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s10157-020-01901-z","volume":"24","author":"K Yamagata","year":"2020","unstructured":"Yamagata K, Usui J, Sugiyama H, Maruyama S, Narita I. Correction to: temporal change in life and renal progressive glomerulonephritis in Japan via nationwide questionnaire survey. Clin Exp Nephrol. 2020;24:976\u20137.","journal-title":"Clin Exp Nephrol"},{"key":"2253_CR8","doi-asserted-by":"publisher","first-page":"775","DOI":"10.7164\/antibiotics.27.775","volume":"27","author":"K Mizuno","year":"1974","unstructured":"Mizuno K, Tsujino M, Takada M, Hayashi M, Atsumi K, Asano K, Matsuda T. Studies on bredinin. I. Isolation, characterization and biological properties. J Antibiot. 1974;27:775\u201382.","journal-title":"J Antibiot"},{"key":"2253_CR9","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1046\/j.1328-8067.2002.01536.x","volume":"44","author":"S Yokota","year":"2002","unstructured":"Yokota S. Mizoribine: mode of action and effects in clinical use. Pediatr Int. 2002;44:196\u20138.","journal-title":"Pediatr Int"},{"key":"2253_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1053\/j.ajkd.2004.03.030","volume":"44","author":"K Hirayama","year":"2004","unstructured":"Hirayama K, Kobayashi M, Hashimoto Y, et al. Treatment with the purine synthesis inhibitor mizoribine for ANCA-associated renal vasculitis. Am J Kidney Dis. 2004;44:57\u201363.","journal-title":"Am J Kidney Dis"},{"key":"2253_CR11","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1248\/bpb.29.2460","volume":"29","author":"M Honda","year":"2006","unstructured":"Honda M, Itoh H, Suzuki T, Hashimoto Y. Population pharmacokinetics of high-dose mizoribine in healthy male volunteers. Biol Pharm Bull. 2006;29:2460\u20134.","journal-title":"Biol Pharm Bull"},{"key":"2253_CR12","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1007\/s10157-011-0487-0","volume":"15","author":"K Ishida","year":"2011","unstructured":"Ishida K, Okamoto M, Ishibashi M, Hashimoto Y. Population pharmacokinetics of mizoribine in adult recipients of renal transplantation. Clin Exp Nephrol. 2011;15:900\u20136.","journal-title":"Clin Exp Nephrol"},{"key":"2253_CR13","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s10157-016-1340-2","volume":"21","author":"T Saito","year":"2017","unstructured":"Saito T, Iwano M, Matsumoto K, et al. The refractory nephrotic syndrome study group. Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome. Clin Exp Nephrol. 2017;21:961\u201370.","journal-title":"Clin Exp Nephrol"},{"key":"2253_CR14","first-page":"283","volume":"66","author":"O Flossmann","year":"2007","unstructured":"Flossmann O, Bacon P, de Groot K, et al. Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis. 2007;66:283\u201392.","journal-title":"Ann Rheum Dis"},{"key":"2253_CR15","first-page":"3643","volume":"28","author":"K Sonda","year":"1996","unstructured":"Sonda K, Takahashi K, Tanabe K, et al. Clinical pharmacokinetic study of mizoribine in renal transplantation patients. Transplant Proc. 1996;28:3643\u20138.","journal-title":"Transplant Proc"},{"key":"2253_CR16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.5414\/CNP63417","volume":"63","author":"H Tanaka","year":"2005","unstructured":"Tanaka H, Tsugawa K, Nakahata T, Kudo M, Suzuki K, Ito E. Implication of the peak serum level of mizoribine for control of the serum anti-dsDNA antibody titer in patients with lupus nephritis. Clin Nephrol. 2005;63:417\u201322.","journal-title":"Clin Nephrol"},{"key":"2253_CR17","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1136\/annrheumdis-2019-216863","volume":"79","author":"RM Smith","year":"2020","unstructured":"Smith RM, Jones RB, Specks U, et al. RITAZAREM coinvestigators. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis. 2020;79:1243\u20139.","journal-title":"Ann Rheum Dis"},{"key":"2253_CR18","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1681\/ASN.V95842","volume":"9","author":"KWA Westman","year":"1998","unstructured":"Westman KWA, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener\u2019s granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol. 1998;9:842\u201352.","journal-title":"J Am Soc Nephrol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-022-02253-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-022-02253-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-022-02253-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T12:17:37Z","timestamp":1666009057000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-022-02253-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,30]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["2253"],"URL":"https:\/\/doi.org\/10.1007\/s10157-022-02253-6","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,30]]},"assertion":[{"value":"7 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Honoraria: TW (Kyowa Kirin Co. Ltd., Mitsubishi Tanabe Pharma Corp.), NH (Takeda Pharmaceutical Co., Ltd.), KY (Chugai, Daiichi-Sankyo, Kyowakirin, Mochida, Tanabe-Mitsubishi, Pfizer, Asteras). Research funding: TW (Shiseido Co., Ltd., Kyowa Kirin Co., Ltd.), YY (Baxter Ltd., Bayer Yakuhin, Ltd., Chugai Pharmaceutical Co., Ltd., Japan Tobacco Inc., Kyowa Kirin Co., Ltd., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sanofi Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Torii Pharmaceutical Co., Ltd.), KY (Kyowakirin, Pfizer, Teijin-pharma, Daiichi-Sankyo, Dainihon-Sumitomo, Takeda, Tanabe-Mitsubishi, Asteras, Chugai). Subsidies or Donations: TW (Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Mitsubishi Tanabe Pharma Corp., MSD K.K., GlaxoSmithKline K.K.).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee at which the studies were conducted (IRB approval no.: University of Tsukuba Hospital, H18-117) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}